Mode
Text Size
Log in / Sign up
N/A N=39 Randomized Double-blind

Multifocal Lens Design Evaluation

Refractive Error · Presbyopia

Enrolled (actual)
39
Serious AEs
0.0%
Results posted
Feb 2014
Primary outcome: Primary: Mean Binocular HC/HI Visual Acuity at Near (40 cm) — 0.08; 0.06; 0.05; 0.05 logMAR

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Delefilcon A multifocal contact lens (Device); Lotrafilcon B multifocal contact lens (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Alcon Research
Primary completion
Nov 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean Binocular HC/HI Visual Acuity at Near (40 cm)
0.08; 0.06; 0.05; 0.05
SECONDARY
Mean Binocular HC/HI Visual Acuity at Distance
-0.06; -0.06; -0.05; -0.05
SECONDARY
Mean Monocular Over-refraction (OR) at Distance
0.08; 0.06; 0.06; 0.03

Summary

The purpose of this study was to compare binocular high contrast, high illumination (HC/HI) visual acuity at near (40 centimeters) of new multifocal contact lenses against AIR OPTIX® AQUA MULTIFOCAL contact lenses when worn for 9 hours.

Eligibility Criteria

Inclusion Criteria

  • Sign written Informed Consent document.
  • Have spectacles that provide acceptable vision and be willing to wear them if unable to wear the study lenses.
  • Be presbyopic with a spectacle add ≥ 0.50 diopter.
  • Currently wearing soft contact lenses at least 5 days a week.
  • Other protocol-specified inclusion criteria may apply

Exclusion Criteria

  • Eye injury or surgery within 12 weeks of enrollment in this trial.
  • Pre-existing ocular irritation that would preclude contact lens fitting.
  • Currently enrolled in any clinical trial.
  • Evidence of systemic or ocular abnormality, infection, or disease which is likely to affect successful wear of contact lenses (for at least 9 hours) or use of their accessory solutions as determined by the Investigator.
  • Any use of medications for which contact lens wear could be contraindicated as determined by the Investigator.
  • Binocular visual acuity worse than 20/25.
  • Corrected by monovision.
  • Other protocol-defined exclusion criteria may apply.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01997216). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search